Routine screening for interstitial lung disease (ILD) is critical for patients with polymyositis (PM) and dermatomyositis (DM), even those who are seronegative for the anti-Jo-1 antibody.
This is a key recommendation from a three-centre study in France led by Dr I. Marie from the Centre Hospitalier Universitaire de Rouen-Boisguillaume, Rouen. Study findings underline the increased morbidity and mortality rates caused by the high frequency of ILD in these patients, these investigators report. As for the need for routine screening of all PM/DM patients, even those without the anti-Jo-1 antibody, 69% of the ILD patients in this study were seronegative for this antibody.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!